Next Article in Journal
Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics
Next Article in Special Issue
Glycosaminoglycans and Proteoglycans
Previous Article in Journal
Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
Previous Article in Special Issue
Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System
Open AccessReview

Heparin Mimetics: Their Therapeutic Potential

School of Biomedical Sciences, Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth 6102, Western Australia, Australia
School of Applied Chemistry, Faculty of Science and Engineering, Curtin University, Perth 6102, Western Australia, Australia
Author to whom correspondence should be addressed.
Pharmaceuticals 2017, 10(4), 78;
Received: 5 July 2017 / Revised: 21 September 2017 / Accepted: 22 September 2017 / Published: 2 October 2017
(This article belongs to the Special Issue Glycosaminoglycans and Proteoglycans)
Heparin mimetics are synthetic and semi-synthetic compounds that are highly sulfated, structurally distinct analogues of glycosaminoglycans. These mimetics are often rationally designed to increase potency and binding selectivity towards specific proteins involved in disease manifestations. Some of the major therapeutic arenas towards which heparin mimetics are targeted include: coagulation and thrombosis, cancers, and inflammatory diseases. Although Fondaparinux, a rationally designed heparin mimetic, is now approved for prophylaxis and treatment of venous thromboembolism, the search for novel anticoagulant heparin mimetics with increased affinity and fewer side effects remains a subject of research. However, increasingly, research is focusing on the non-anticoagulant activities of these molecules. Heparin mimetics have potential as anti-cancer agents due to their ability to: (1) inhibit heparanase, an endoglycosidase which facilitates the spread of tumor cells; and (2) inhibit angiogenesis by binding to growth factors. The heparin mimetic, PI-88 is in clinical trials for post-surgical hepatocellular carcinoma and advanced melanoma. The anti-inflammatory properties of heparin mimetics have primarily been attributed to their ability to interact with: complement system proteins, selectins and chemokines; each of which function differently to facilitate inflammation. The efficacy of low/non-anticoagulant heparin mimetics in animal models of different inflammatory diseases has been demonstrated. These findings, plus clinical data that indicates heparin has anti-inflammatory activity, will raise the momentum for developing heparin mimetics as a new class of therapeutic agent for inflammatory diseases. View Full-Text
Keywords: heparin mimetics; heparin; heparan sulfate; glycosaminoglycan; anticoagulant; cancer; anti-inflammatory heparin mimetics; heparin; heparan sulfate; glycosaminoglycan; anticoagulant; cancer; anti-inflammatory
Show Figures

Figure 1

MDPI and ACS Style

Mohamed, S.; Coombe, D.R. Heparin Mimetics: Their Therapeutic Potential. Pharmaceuticals 2017, 10, 78.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop